Ambroxol to Slow Progression in Parkinson Disease

Phase 3RecruitingNCT05778617

University College, London330 enrolled

Overview

This is a UK only clinical trial in patients with Parkinson's disease (PD) of a drug called ambroxol hydrochloride, which is an already licensed drug for the treatment of respiratory conditions (such as a common cold) in many European countries. The aim of this trial is to find out whether ambroxol hydrochloride can slow down the progression of Parkinson's disease and to evaluate it's safety and tolerability.

This is a 104-week, randomized, double-blind, multi-centre, parallel group, placebo-controlled clinical trial of ambroxol hydrochloride in patients with PD, with a 26-week open-label extension phase. Participants will undergo screening to evaluate their eligibility to participate in the trial. All eligible participants will be randomised to receive either ambroxol hydrochloride (420mg) or it's matching placebo in a 1:1 ratio three times a day for 104 weeks, including a 2-week dose escalation period. Once the end of the blinded treatment has been reached, all participants will enter the open-label extension phase and will receive ambroxol hydrochloride (420mg) three times a day for 26 weeks, including a 2-week dose escalation period. All clinical staff, study investigators, and participants will be blinded to study assignments throughout the entirety of the trial. There will be an optional sub-study including 106 participants in which a cerebrospinal fluid (CSF) sample will be taken on two occasions via a Lumbar Puncture procedure to measure ambroxol drug levels, assess whether the glucocerebrosidase enzyme has been stimulated and the levels of other substances thought to be associated with the development of PD and confirm whether the study drug has penetrated the cerebrospinal fluid and Central Nervous System.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

330

Conditions

Parkinson Disease

Interventions

Ambroxol Hydrochloride (420mg)DRUG

Oral tablet

PlaceboDRUG

Oral tablet

Eligibility

Sex: ALLMin age: 35 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. A diagnosis of Parkinson's disease (in accordance with the MDS diagnostic criteria) within 7 years of the screening visit confirmed by year of diagnosis. 2. Adults aged ≥ 35 and ≤ 75 years. 3. Hoehn and Yahr stage between 1-2.5, inclusive (in ON stage) at screening visit. 4. Known glucocerebrosidase gene (GBA1) status, positive or negative (status MUST be confirmed prior to screening). 5. On stable dopaminergic treatment for at least 3 months before enrolment. 6. Able and willing to provide informed consent prior to any study related assessments and/or procedures. 7. Able and willing to attend trial visits and comply with all study procedures for the duration of the trial. 8. Willing and able to self-administer oral ambroxol medication or placebo. Exclusion Criteria: 1. Participation in another interventional clinical trial of an Investigational Medicinal Product (IMP) and use of an Investigational Medicinal Product (IMP) within 90 days prior to the first dose of trial treatment. 2. Use of an Investigational Medicinal Product (IMP) within 90 days prior to the first dose of trial treatment. 3. Participation in another clinical trial of an Investigational New Drug being tested for PD disease modifying potential within 12 months prior to the first dose of trial treatment. 4. Past surgical history of deep brain stimulation. 5. Use of ambroxol in the past 12 months. 6. Exposure to Exenatide within 12 months prior to the first dose in this current trial. 7. Concomitant medications that in the opinion of the Investigator would preclude participation in the study e.g., exenatide or other GLP1 agonist for diabetes. 8. Confirmed dysphagia that would preclude self-administration of ambroxol. 9. History of known sensitivity to the study medication, ambroxol or its excipients (lactose monohydrate, granulated microcrystalline cellulose, copovidone and magnesium stearate) in the opinion of the investigator that contraindicates their participation. 10. History of known rare hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. 11. Presence of the LRRK2 G2019S mutation (status to be confirmed prior to screening). 12. History of drug abuse or alcoholism in the opinion of the Investigator that would preclude participation in the trial. 13. Pregnant (or planned pregnancy during the trial) and/or breastfeeding. 14. Women of childbearing potential (WOCBP) and male participants with a partner of childbearing potential not willing to use highly effective contraception or abstinence for the duration of the trial treatment and for 2 weeks following the last dose of the study drug. 15. Any clinically significant or unstable medical or surgical condition that in the opinion of the Investigator may; put the participant at risk when participating in the study, influence the results of the study or affect the participants ability to take part in the study, as determined by medical history, physical examinations, electrocardiogram (ECG) or laboratory tests. Such conditions may include: A. Impaired renal function with creatinine clearance \<50ml/min at screening visit. B. Moderate/Severe hepatic impairment. C. A major cardiovascular event (e.g., myocardial infarction, acute coronary syndrome, compensated congestive heart failure, pulmonary embolism, coronary revascularisation) that occurred within 6 months prior to the screening visit. 16. Severe depression defined by a score \>20 on the Beck Depression Inventory-II (BDI-II) at screening. 17. Significant cognitive impairment defined by a score \<20 on the Montreal Cognitive Assessment (MoCA) at screening. 18. Use of trihexyphenidyl or benztropine within 30 days prior to the first dose of trial treatment. 19. Only applicable for those patients consenting to the optional CSF sub-study: Evidence or history of hypersensitivity to lidocaine or its derivatives. 20. Only applicable for those patients consenting to the optional CSF sub-study: current treatment with anti-coagulants (e.g., warfarin) that might preclude safe completion of the lumbar puncture in the opinion of the Investigator. Aspirin will be permitted. 21. Only applicable for those patients consenting to the optional CSF sub-study: Significant known lower spinal malformations or other spinal abnormalities that would preclude a lumbar puncture.

Locations (15)

University Hospitals Birmingham

Birmingham, United Kingdom

NOT_YET_RECRUITING

Southmead Hospital Bristol

Bristol, United Kingdom

Outcomes

Primary Outcomes

Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I- III score from baseline to Week 104.

The MDS-UPDRS is a comprehensive 50 question assessment of both motor and non-motor symptoms associated with Parkinson's. Comparison of MDS-UPDRS Parts I-III total score at 104 weeks between participants according to treatment allocation will be made. Parts I and II are measured in the practically defined ON medication state and Part III is measured in the practically defined OFF medication state. Parts I and II are historical data assessed by an examiner and are designed to rate mentation, behaviour and mood; Part III is done as a motor examination at the time of a visit. Participants will undergo MDS-UPDRS assessment at baseline, week 20, week 40, week 60, week 80, week 104. The MDS-UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario. MDS-UPDRS score = sum of Parts I, II and III (Range: 0 to 236). Higher score indicative of worse outcome.

Time frame: Baseline; Week 104

Secondary Outcomes

Motor signs of PD using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III score in the OFF medication state from baseline to Week 104.

This component of the MDS-UPDRS scale (Section III) assesses the motor signs of PD and will involve a motor examination at the time of a visit. The score ranges from 0 to 132. Higher score is indicative of worse outcome.

Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.

Motor complications of PD using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV score in the ON medication state from baseline to Week 104.

This component of the MDS-UPDRS scale (Section IV) assesses two motor complications, dyskinesias and motor fluctuations using historical and objective information. The score ranges from 0 to 24. Higher score indicative of worse outcome.

Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.

The non-motor impact of PD on patients using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part I score in the ON medication state baseline to Week 104.

Central Contacts

ASPro-PD Trial Team

CONTACT

02031084908 cctu.aspro-pd@ucl.ac.uk

Felicia Ikeji

CONTACT

02076799506 f.ikeji@ucl.ac.uk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Addenbrookes NHS Trust

Cambridge, United Kingdom

NOT_YET_RECRUITING

Western General Hospital

Edinburgh, United Kingdom

NOT_YET_RECRUITING

Kings College London

London, United Kingdom

NOT_YET_RECRUITING

Royal London Hospital

London, United Kingdom

NOT_YET_RECRUITING

University College London Hospital's

London, United Kingdom

RECRUITING

Newcastle

Newcastle, United Kingdom

NOT_YET_RECRUITING

Northumbria

Newcastle upon Tyne, United Kingdom

NOT_YET_RECRUITING

The John Radcliffe Hospital

Oxford, United Kingdom

NOT_YET_RECRUITING

...and 5 more locations

This component of the MDS-UPDRS scale (Section I) assesses the non-motor impact of Parkinson's disease (PD) on patients' experiences of daily living. The score ranges from 0 to 24. Higher score indicative of worse outcome.

Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.

The motor aspect impact of PD of patients experiences on daily living using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II score in the ON medication state from baseline to Week 104.

This component of the MDS-UPDRS scale (Section II) assesses the motor aspect impact of Parkinson's disease (PD) on patients' experiences of daily living. The score ranges from 0 to 52. Higher score indicative of worse outcome.

Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.

The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) tremor score from baseline to Week 104.

The tremor components of the MDS-UPDRS scale

Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.

The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) non-tremor score from baseline to Week 104.

The non-tremor components of the MDS-UPDRS scale

Time frame: Baseline; Week 20; Week 40; Week 60; Week 80; Week 104.

Cognitive impairment using the Montreal Cognitive Assessment from baseline to Week 104.

A 30 question test which assesses mild cognitive impairment by checking participant orientation, short-term memory, executive function, language, abstraction, naming of animals, attention and a clock drawing test. Maximum score= 30. Lower scores indicative of worse outcome.

Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

Patient reported measure of health status and quality of life using the Parkinson's disease 39 item Quality of Life questionnaire from baseline to Week 104.

A questionnaire which assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living. The 39 item questionnaire offers a patient reported measure of health status and quality of life and is the most frequently used disease-specific health status measure. Maximum score = 156. Higher score= worse outcome.

Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

Symptom improvement from baseline to Week 104 using the Patient Global Impression of Change from baseline to Week 104.

A 1 item questionnaire which asks a participant to report their own impression of change in their clinical status. Maximum score = 7. Higher score= worse outcome.

Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

Quality-of-Life outcome differences between the two treatment groups from baseline to Week 104, as measured by the descriptive system for health-related quality of life, EQ-5D-5L.

The EQ-5D-5L is a participant self-reported questionnaire which evaluates the generic quality of life at the time of completion. It comprises of one question for each of the five dimensions ;no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. An Visual Analogue Scale is also used and is a scale measured from 0 -100 scale where patients are asked to indicate their overall health on the day of questionnaire completion. Maximum score = 100. Lower score = worse outcome.

Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

Non-motor symptoms of PD from baseline to Week 104 , as measured by the Non-Motor Symptoms Scale.

The Non-Motor Symptoms Scale (NMSS) is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. Maximum score = 360. Higher score = worse outcome.

Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

PD progression measured using Parkinson's Disease Comprehensive Response from baseline to Week 104

A composite approach integrating three standard outcome measures PDCORE = (1 × change in OFF state motor score) + (2 × change in OFF state ADL score) - (10 × change in total good-quality ON time per day). Higher score = worse outcome.

Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

Assessment of postural instability and falls from baseline to Week 104 using the Dresden Falls Questionnaire.

A self-reported assessment of falls, near falls, fear of falling, fall-related injuries, and causes of falls for patients with Parkinson's disease. Maximum score = 12. Higher score = worse outcome.

Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

Symptom severity, treatment response and the efficacy of treatment from baseline to Week 104 using the Clinical Global Impression of symptom severity and improvement scales.

Research team assessment. The CGI has two components-the CGI-Severity, which rates illness severity, and the CGI-Improvement, which rates change from the initiation (baseline) of treatment. Maximum score = 14. Higher score = worse outcome.

Time frame: At Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

Safety and tolerability of ambroxol hydrochloride as indicated by changes in pulse (bpm) from baseline to Week 104

Vital signs

Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

Safety and tolerability of ambroxol hydrochloride as indicated by changes in blood pressure (mmHg) from baseline to Week 104

Vital signs

Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

Safety and tolerability of ambroxol hydrochloride as indicated by changes in temperature (°) from baseline to Week 104

Vital signs

Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

Safety and tolerability of ambroxol hydrochloride as indicated by changes in respiratory rate (breaths per minute)from baseline to Week 104

Vital signs

Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

Safety and tolerability of ambroxol hydrochloride as indicated by changes in Body Mass Index (weight and height will be combined to report BMI in kg/m^2) from baseline to Week 104

Vital signs

Time frame: At Screening; Baseline; Week 20; Week 40; Week 60; Week 80; Week 104

Safety and tolerability of ambroxol hydrochloride as indicated by changes in Red Blood Cell Count (10^12/L) from baseline to Week 104

Standard diagnostic laboratory test (Full Blood Count)